RSC Pharmaceutics最新文献_第6页

Alditols in complex with boronophenylalanine for improving aqueous solubility for boron neutron capture therapy 与硼苯丙氨酸配合的糖醇改善硼中子俘获治疗的水溶性

RSC Pharmaceutics Pub Date : 2025-11-18 DOI: 10.1039/D5PM00180C

Teng-San Hsieh, Yu-Hou Yu, Zhen-Fan You, Rong-Jiun Sheu, Jin-Pei Deng and Chung-Shan Yu

{"title":"Alditols in complex with boronophenylalanine for improving aqueous solubility for boron neutron capture therapy","authors":"Teng-San Hsieh, Yu-Hou Yu, Zhen-Fan You, Rong-Jiun Sheu, Jin-Pei Deng and Chung-Shan Yu","doi":"10.1039/D5PM00180C","DOIUrl":"https://doi.org/10.1039/D5PM00180C","url":null,"abstract":"Boron neutron capture therapy (BNCT) aimed at treating brain tumors is deteriorated by the poor aqueous solubility of the BNCT agent, boronophenylalanine (BPA). Solubilizers, such as sorbitol, mannitol and xylitol and their mixing formulas, the storage temperature and time, acid adjusters, and antioxidants, as well as lyophilization conditions were studied. HPLC, 1H-NMR, and scanning electron microscopy (SEM) were used to investigate the alditol–BPA samples. HPLC results showed that the stability of sorbitol–BPA samples improved when the antioxidant Na2S2O5 was used, 98.25 ± 0.31% vs. 94.37 ± 1.24%, P < 0.05. The osmolality ratio of sorbitol–BPA, 0.83 ± 0.03, was lower than that of saline, 1.0, making it physiologically compatible. SEM results of the lyophilized samples showed a proportion of sorbitol–BPA vs. H2O in a molar ratio of 1 : 10. Sorbitol was the best solubilizer according to the 1H-NMR-derived integral ratio in the decreasing order of sorbitol–BPA, mannitol–BPA, fructose–BPA and xylitol–BPA with the values of 12.15 ± 1.30, 6.65 ± 0.61, 6.13 ± 1.90 and 4.77 ± 0.72, P < 0.05, respectively. The antioxidant Na2S2O5 improved the stability of sorbitol–BPA at 25 °C according to the 1H-integral ratio of 17.60 ± 2.15 vs. 12.67 ± 1.62, P = 0.10. The differences were not statistically significant. From both the HPLC and 1H-integral results, sorbitol emerges as the optimal solubilizer for PBA for further in vivo studies.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 247-255"},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00180c?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Formulation and evaluation of a Tridax procumbens-loaded phospholipid complex (phytosome) gel for wound healing and antimicrobial activities 用于伤口愈合和抗菌活性的磷脂复合物（光敏体）凝胶的制备和评价

RSC Pharmaceutics Pub Date : 2025-11-18 DOI: 10.1039/D5PM00243E

Priyanka S. Jadhav, Priyanka H. Shinde and Jameel Ahmed S. Mulla

{"title":"Formulation and evaluation of a Tridax procumbens-loaded phospholipid complex (phytosome) gel for wound healing and antimicrobial activities","authors":"Priyanka S. Jadhav, Priyanka H. Shinde and Jameel Ahmed S. Mulla","doi":"10.1039/D5PM00243E","DOIUrl":"https://doi.org/10.1039/D5PM00243E","url":null,"abstract":" Tridax procumbens is a widely recognized medicinal plant known for its remarkable antimicrobial and wound-healing effects. Nevertheless, its therapeutic efficacy is often restricted due to low bioavailability. This study aimed to formulate and evaluate a Tridax procumbens-loaded phospholipid complex (phytosome) gel to enhance its transdermal delivery and therapeutic efficacy. The optimization of the phytosomal gel was conducted using a central composite design, where soy lecithin and cholesterol were the primary independent variables affecting particle size and entrapment efficiency. The ideal formulation showed a particle diameter of 460.2 nm and a loading capacity of 93.14%, ensuring improved permeation and prolonged drug release. Antimicrobial studies demonstrated improved efficacy against E. coli, with the phospholipid complex gel exhibiting a zone of inhibition (ZOI) of 32 mm, compared to 28 mm for the ethanolic extract and 30 mm for the standard drug amikacin. In vitro wound healing studies using L929 fibroblast cells showed that the phospholipid complex gel achieved 54.34% wound closure after 48 hours, compared to 41.57% for the ethanolic extract and 87.53% for the standard drug cipladine. These results suggest that the phospholipid complex (phytosome) system significantly enhances the bioavailability and therapeutic potential of Tridax procumbens for wound healing and antimicrobial applications.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 237-246"},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00243e?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improved localized mRNA delivery using lipid nanoparticles with a novel synthetic cholesterol derivative 利用脂质纳米颗粒和一种新型合成胆固醇衍生物改善mRNA的局部递送。

RSC Pharmaceutics Pub Date : 2025-11-12 DOI: 10.1039/D5PM00166H

Deepak K. Sahel, Jonas Renner, Kseniia Yu. Vlasova, Nathan D. Pennock, Sakib T. Haque, Antony Jozic, Joshua M. Walker, Conroy Sun and Gaurav Sahay

{"title":"Improved localized mRNA delivery using lipid nanoparticles with a novel synthetic cholesterol derivative","authors":"Deepak K. Sahel, Jonas Renner, Kseniia Yu. Vlasova, Nathan D. Pennock, Sakib T. Haque, Antony Jozic, Joshua M. Walker, Conroy Sun and Gaurav Sahay","doi":"10.1039/D5PM00166H","DOIUrl":"10.1039/D5PM00166H","url":null,"abstract":"Lipid nanoparticles (LNPs) are self-assembled nanocarriers made up of ionizable cationic lipids, membrane lipids, sterols, and PEGylated lipids in a predetermined proportion to encapsulate nucleic acid payloads. According to recent findings, following local administration (intramuscular, intratumoral), LNPs diffuse into the systemic circulation and subsequently show liver transfection. Liver transfection can result in both liver toxicity and undesirable cargo distribution. To address this issue, we synthesized a novel cholesterol derivative, glutamate–cholesterol (GA–Chol), which, when incorporated in LNPs (GA–Chol LNPs), improved in vitro transfection efficiency by approximately 10-fold and 20-fold in HEK293T and HeLa cells, respectively. Furthermore, when GA–Chol LNPs were injected intramuscularly or intratumorally, robust localized transfection was observed in either the injected muscle or the flank tumors, without significant transfection in the liver. This observation was consistent across multiple cell lines, representing various types of cancer. Leverage local delivery strategy, mRNA encoding for constitutively active caspase-3 was encapsulated with GA–Chol LNPs and delivered intratumorally in 4T1 tumor-bearing BALB/c mice, resulting in a significantly reduced and sustained tumor burden. Overall, these findings describe the potential application of a synthetic cholesterol derivative for the localized transfection of LNPs.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 187-197"},"PeriodicalIF":0.0,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12606572/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145515506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic development and optimization of a microfluidic formulation protocol for liposomal azithromycin 阿奇霉素脂质体微流控处方的系统开发与优化。

RSC Pharmaceutics Pub Date : 2025-11-12 DOI: 10.1039/D4PM00275J

Abdullah A. Masud, Nabilah Ibnat, Areli Medina Hernandez, Kaysi M. Lee, Sophia Li, Ryan Marion, David J. Feola and Vincent J. Venditto

{"title":"Systematic development and optimization of a microfluidic formulation protocol for liposomal azithromycin","authors":"Abdullah A. Masud, Nabilah Ibnat, Areli Medina Hernandez, Kaysi M. Lee, Sophia Li, Ryan Marion, David J. Feola and Vincent J. Venditto","doi":"10.1039/D4PM00275J","DOIUrl":"10.1039/D4PM00275J","url":null,"abstract":"Delivery of azithromycin via liposomal formulation (L-AZM) has been shown to improve the therapeutic index and activity of AZM in a preclinical model of cardiac injury, suggesting strong potential for clinical translation to treat inflammation after a myocardial infarction. However, conventional thin film hydration (TFH) utilized to prepare L-AZM limits its clinical development due to scalability and reproducibility concerns. To overcome these manufacturing challenges, we performed a systematic optimization of the L-AZM formulation utilizing microfluidic nanoprecipitation which has been successfully used for large scale manufacturing of lipid-based therapeutics in a reproducible manner. We adjusted the microfluidic operation parameters and evaluated the resultant liposomes for critical quality attributes (CQAs) of size, polydispersity index (PDI), encapsulation efficiency, and leakage. The optimal flow rate ratio (FRR) and total flow rate (TFR) for the lead formulation was determined to be 4 : 1 and 10 mL min−1, respectively. Utilizing these manufacturing parameters with formulations of different molar ratios resulted in an optimized formulation consisting of DSPC : DSPG : Chol : AZM (1 : 1 : 1 : 0.5) based on the CQAs with decreased size and PDI as compared to TFH. Notably, there is no difference in in vitro macrophage polarization activity between the two formulation methods. Collectively, these data guide continued preclinical development as we advance this formulation toward clinical use.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 198-208"},"PeriodicalIF":0.0,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12633639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145591057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spray-dried inhalable nano-embedded microparticles of isoniazid and pyridoxine hydrochloride for pulmonary tuberculosis 雾化干燥可吸入的异烟肼和盐酸吡哆醇纳米包埋微粒治疗肺结核

RSC Pharmaceutics Pub Date : 2025-11-06 DOI: 10.1039/D5PM00118H

Eknath Kole, Krishna Jadhav, Priya Chichmalkar, Rahul K. Verma, Arun Mujumdar and Jitendra Naik

{"title":"Spray-dried inhalable nano-embedded microparticles of isoniazid and pyridoxine hydrochloride for pulmonary tuberculosis","authors":"Eknath Kole, Krishna Jadhav, Priya Chichmalkar, Rahul K. Verma, Arun Mujumdar and Jitendra Naik","doi":"10.1039/D5PM00118H","DOIUrl":"https://doi.org/10.1039/D5PM00118H","url":null,"abstract":"Tuberculosis (TB) is the second deadliest communicable disease caused by Mycobacterium tuberculosis and mainly affects the lungs. Current TB therapy typically involves the oral administration of antitubercular drugs (ATDs). However, this approach is often associated with challenges, such as drug toxicity, suboptimal pulmonary drug concentration, and issues with patient adherence. Moreover, isoniazid (INH) therapy frequently induces pyridoxine (PDX) deficiency in TB patients, potentially leading to neuropathy. In this study, INH–PDX nano-embedded microparticles (NEMs) were developed as a dry powder formulation to enhance pulmonary TB treatment. The formulation was optimised using a microreactor through a three-factor, three-level Box–Behnken design (BBD). The optimised dry powder achieved a product yield of 48.36% (w/w) and a drug-loading efficiency of 24.14 ± 2.86% (w/w). The particles exhibited a spherical morphology. Furthermore, aerosolization performance demonstrated the formulation's suitability for deep lung deposition, with a mass median aerodynamic diameter (MMAD) of 5.97 ± 1.10 µm, a fine particle fraction (FPF) of 36.63 ± 3.12%, and a geometric standard deviation (GSD) of 1.73 ± 0.23. In conclusion, the Design of Experiments (DoE)-based optimisation approach successfully optimised the process parameters and produced a dry powder formulation suitable for pulmonary delivery in patients with TB, addressing both treatment efficacy and neuropathy concerns.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 220-236"},"PeriodicalIF":0.0,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00118h?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemotherapeutic loaded dynamic aggregated albumin nanoparticles for lung cancer therapy 化疗负载动态聚集白蛋白纳米颗粒用于肺癌治疗

RSC Pharmaceutics Pub Date : 2025-11-04 DOI: 10.1039/D5PM00136F

Jyotish Kumar, Sourima Kundu, Asmita Mojumdar, B. S. Unnikrishnan, Devika B. Chithrani and Gopinath Packirisamy

{"title":"Chemotherapeutic loaded dynamic aggregated albumin nanoparticles for lung cancer therapy","authors":"Jyotish Kumar, Sourima Kundu, Asmita Mojumdar, B. S. Unnikrishnan, Devika B. Chithrani and Gopinath Packirisamy","doi":"10.1039/D5PM00136F","DOIUrl":"https://doi.org/10.1039/D5PM00136F","url":null,"abstract":"The development of safe and effective anticancer drugs remains a significant challenge for the scientific community. A broad range of chemotherapeutic agents has been extensively evaluated for their efficacy across various patient populations. Among them, epirubicin has exhibited strong anti-cancer potential across different tumor models. In this study, epirubicin-loaded bovine serum albumin nanoparticles (EPI@BSA) were prepared using the desolvation method to explore their potential in lung cancer therapy. Physicochemical characterization confirmed that the nanoparticles were spherical and highly monodispersed. Cytotoxicity testing on the A549 cell line revealed enhanced cell death with the nanoparticle formulation compared to that with the free drug. Furthermore, semi-quantitative RT-PCR analysis indicated that the nanoparticles effectively induced apoptosis. These findings support the potential of a protein-based biodegradable carrier system to enhance the therapeutic efficacy of epirubicin in cancer treatment.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 209-219"},"PeriodicalIF":0.0,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00136f?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sustained drug delivery of the β-blocker acebutolol hydrochloride via chitosan–bilimbi leaf extract films 壳聚糖-枸橼酸叶提取物膜对β受体阻滞剂盐酸乙酰布洛尔的持续给药作用

RSC Pharmaceutics Pub Date : 2025-10-31 DOI: 10.1039/D5PM00172B

Jennifer P. Pinto, Manjunath B. Megalamani, Ajitkumar Appayya Hunashyal, Oshin Jacintha D′souza, Sharanappa T. Nandibewoor, Saraswati P. Masti and Ravindra B. Chougale

{"title":"Sustained drug delivery of the β-blocker acebutolol hydrochloride via chitosan–bilimbi leaf extract films","authors":"Jennifer P. Pinto, Manjunath B. Megalamani, Ajitkumar Appayya Hunashyal, Oshin Jacintha D′souza, Sharanappa T. Nandibewoor, Saraswati P. Masti and Ravindra B. Chougale","doi":"10.1039/D5PM00172B","DOIUrl":"https://doi.org/10.1039/D5PM00172B","url":null,"abstract":"This study presents the development of biocompatible polymeric films designed for the sustained release of the β-blocker acebutolol hydrochloride (AH). The films were fabricated using chitosan (CH), a biodegradable biopolymer, in combination with varying concentrations of Averrhoa bilimbi leaf extract (ABE), a natural additive with potential antimicrobial properties. The composite films were characterized using crystallinity, spectroscopic, mechanical, thermal, and morphological analyses. Functional testing included swelling studies, cumulative drug release profiling, cytotoxicity assessments, and microbial resistance assessments. The results indicated that the incorporation of ABE positively influenced the structural, mechanical, thermal and morphological properties, including swelling behaviour, thickness, and drug release kinetics. The film with the lowest ABE concentration showed optimal swelling (∼200%) and the highest drug release (∼25%), along with notable drug loading (∼78%) and encapsulation efficiency (∼19%). The release kinetics followed the Higuchi and Korsmeyer–Peppas models, indicating a non-Fickian diffusion mechanism. Importantly, the AH integrity was maintained throughout the fabrication process, and all the films exhibited excellent biocompatibility (90% cell viability rate). These findings support the feasibility of using CH/ABE films as promising candidates for sustained drug delivery systems. The use of plant-based and biodegradable components underscores the potential of this green strategy in pharmaceutical formulations, contributing to sustainable chemistry and reducing the environmental impact in drug delivery applications.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 150-167"},"PeriodicalIF":0.0,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00172b?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic drug delivery in pigs using biodegradable microneedle patches 利用可生物降解的微针贴片给猪全身给药

RSC Pharmaceutics Pub Date : 2025-10-30 DOI: 10.1039/D5PM00203F

Katherine A. Miranda-Muñoz, Tsungcheng Tsai, Jacy L. Riddle, Ke He, Lee Blaney, Jeremy G. Powell and Jorge Almodovar

{"title":"Systemic drug delivery in pigs using biodegradable microneedle patches","authors":"Katherine A. Miranda-Muñoz, Tsungcheng Tsai, Jacy L. Riddle, Ke He, Lee Blaney, Jeremy G. Powell and Jorge Almodovar","doi":"10.1039/D5PM00203F","DOIUrl":"https://doi.org/10.1039/D5PM00203F","url":null,"abstract":"Transdermal microneedle systems offer a minimally invasive strategy for systemic drug delivery in veterinary medicine. In this study, biodegradable microneedle patches composed of polyvinyl alcohol, collagen, and chitosan were evaluated in pigs for the delivery of two model compounds, fluorescein isothiocyanate–dextran (FITC-dextran, 4 kDa) and flunixin meglumine (FLU). Patches were applied to the ear and neck to assess the influence of anatomical site on systemic absorption. FITC-dextran delivered via a single 50 mg patch on the neck achieved approximately 1.2–1.4-fold higher plasma concentrations than oral administration and ear-applied patches, demonstrating enhanced uptake from vascularized regions. FLU patches applied to the ear produced detectable plasma levels up to 72 h post-application, with a maximum concentration of ∼1.9 μg L−1 at 24–48 h, indicating sustained systemic exposure and reinforcing the potential for long-acting therapy. No adverse tissue responses were observed at application sites, highlighting the safety and tolerability of the patches. Overall, these findings emphasize the importance of anatomical site selection, physicochemical properties, and biocompatibility in optimizing microneedle-mediated transdermal drug delivery for veterinary applications.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 67-76"},"PeriodicalIF":0.0,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00203f?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

4D printing innovations and the embracing of additive manufacturing transformations 4D打印创新和增材制造转型的拥抱

RSC Pharmaceutics Pub Date : 2025-10-28 DOI: 10.1039/D5PM00192G

Debarupa Dutta Chakraborty, Prithviraj Chakraborty, Subhasish Pramanik, Manali Dutta, Arpan Sen, Sudarshana Borah, Pallab Kumar Nath and Sabnam Nargis

{"title":"4D printing innovations and the embracing of additive manufacturing transformations","authors":"Debarupa Dutta Chakraborty, Prithviraj Chakraborty, Subhasish Pramanik, Manali Dutta, Arpan Sen, Sudarshana Borah, Pallab Kumar Nath and Sabnam Nargis","doi":"10.1039/D5PM00192G","DOIUrl":"https://doi.org/10.1039/D5PM00192G","url":null,"abstract":"The transition from 3D to 4D printing has revolutionized additive manufacturing by introducing dynamic shape-changing capabilities. The limitations of 3D printing have led to the development of 4D printing, which uses ultraviolet light to deposit materials layer-by-layer, creating customizable soft fabric structures that can transform over time in response to external stimuli. The stimuli can be physical, chemical, or biological. Predetermined interaction mechanisms and mathematical modelling, facilitated by tools such as CAD and FEEA, play crucial roles in orchestrating these shape-shifting behaviours. 4D printing has applications in the medical, manufacturing, and educational sectors, with applications extending to adaptive medical implants and devices. Research on 4D printing focuses on various shape alterations, with promising transformative effects on manufacturing processes, medical interventions, and educational tools. As 4D printing progresses, it has the potential to revolutionize industries and provide innovative solutions to complex challenges. The interplay between stimuli and responsive materials, guided by advanced modelling techniques, opens new avenues for unprecedented development. The shift from 3D to 4D printing signifies a paradigm change in additive manufacturing, offering a glimpse into the future, where products dynamically adapt to their environment and user needs.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 22-42"},"PeriodicalIF":0.0,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00192g?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of guide RNA thermal denaturation on the quality of Cas9 ribonucleoprotein-loaded lipid nanoparticle formulations 引导RNA热变性对Cas9核糖核蛋白负载脂质纳米颗粒配方质量的影响

RSC Pharmaceutics Pub Date : 2025-10-27 DOI: 10.1039/D5PM00189G

Rina Shimizu, Yuji Kashiwakura, Morisada Hayakawa, Shunsuke Kita, Mina Sato, Masatoshi Maeki, Manabu Tokeshi, Katsumi Maenaka, Tsukasa Ohmori, Yuma Yamada, Hideyoshi Harashima and Yusuke Sato

{"title":"The effect of guide RNA thermal denaturation on the quality of Cas9 ribonucleoprotein-loaded lipid nanoparticle formulations","authors":"Rina Shimizu, Yuji Kashiwakura, Morisada Hayakawa, Shunsuke Kita, Mina Sato, Masatoshi Maeki, Manabu Tokeshi, Katsumi Maenaka, Tsukasa Ohmori, Yuma Yamada, Hideyoshi Harashima and Yusuke Sato","doi":"10.1039/D5PM00189G","DOIUrl":"https://doi.org/10.1039/D5PM00189G","url":null,"abstract":"Gene-editing technology for the treatment of genetic diseases uses a system that delivers clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) 9 as ribonucleoproteins (RNPs) in a faster and more transiently effective manner than other delivery methods that involve gene expression. Lipid nanoparticles (LNPs) are an integral part of technology that is used to deliver Cas9 RNPs, and in recent years the in vivo delivery of RNPs has been achieved. While single-guide RNA (sgRNA) forms complex higher-order structures, which are known to result in the formation of heterogeneous RNPs, the impact on RNP-loaded LNP formulations has been overlooked. The results of this study show that the heterogeneity of sgRNA significantly affects the internal structure, physical properties, and knockout activity of RNP-loaded LNP formulations through changes in molecular weight distribution and RNP charge.","PeriodicalId":101141,"journal":{"name":"RSC Pharmaceutics","volume":" 1","pages":" 77-87"},"PeriodicalIF":0.0,"publicationDate":"2025-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.rsc.org/en/content/articlepdf/2026/pm/d5pm00189g?page=search","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0